RenovoRx, Inc. RNXT 深 滬
等待開盤 05-27 09:30:00 美东时间
0.9318
+0.050
+5.71%
華盛通- 最 高0.94
- 今 開0.8814
- 成交量 38.36万股
- 最 低 0.8421
- 昨 收 0.8815
- 總市值 4202.34万
- 52周最高 1.45
- 市盈率 靜 --
- 換手率 0.85%
- 52周最低 0.7006
- 委 比 -96.98%
- 總股本 4509.91万
- 歷史最高 16.74
- 量 比 1.62
- 振 幅 11.11%
- 歷史最低 0.5306
- 每 手 1
- 風險率 0.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多RenovoRx Announces Online Publication Of Abstract From Pharmacokinetic And Pharmacodynamic Sub-Study Of Ongoing Phase III TIGeR-PaC Clinical Trial In Connection With 2026 ASCO Annual Meeting
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common
05-26 20:41
RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript
RenovoRx (NASDAQ:RNXT) released first-quarter financial results and hosted an e...
05-15 05:04
RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est.
RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 million-$4.000 million vs $3.244 million estimate.
05-15 04:13
RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate.
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year. The
05-15 04:12
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
美股大行评级 | 瑞银上调美光科技目标价从510升至535美元；巴克莱下调Robinhood 目标价从124降至89美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5美元升至5.25美元；Benchmark：维持Direct Digital Holdings"投机性买入"评级，目标价从2美元升至8美元
04-09 10:15
RenovoRx Secures Notice Of Allowance From Japan Patent Office For Application Titled "Method and Apparatus for Delivering an Agent Through the Vasa Vasorum"
The allowed claims of the patent protect the RenovoCath dual-occlusion catheter-based system equipped with integrated imaging and pressure-sensing technology that is designed to enable targeted localization and
04-08 20:34
RenovoRx Q4 EPS $(0.08), Inline, Sales $238.000K Miss $419.750K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.12) per share from the same period last year. The
03-31 04:22
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
